COMPASS Pathways plc (NASDAQ:CMPS) Receives $33.60 Average PT from Analysts

COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) has been given a consensus rating of "Buy" by the six analysts that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $33.60.

CMPS has been the topic of a number of research analyst reports. Royal Bank of Canada cut their target price on shares of COMPASS Pathways from $23.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. HC Wainwright reduced their price objective on COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Finally, Maxim Group dropped their target price on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, November 1st.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Green Alpha Advisors LLC increased its holdings in COMPASS Pathways by 138.3% in the fourth quarter. Green Alpha Advisors LLC now owns 37,614 shares of the company's stock worth $142,000 after purchasing an additional 21,833 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of COMPASS Pathways by 4.4% during the 3rd quarter. Franklin Resources Inc. now owns 295,785 shares of the company's stock valued at $1,810,000 after acquiring an additional 12,599 shares during the period. Geode Capital Management LLC boosted its stake in COMPASS Pathways by 160.3% during the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company's stock worth $266,000 after acquiring an additional 25,970 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in COMPASS Pathways in the third quarter worth $131,000. Finally, Point72 Asset Management L.P. bought a new stake in COMPASS Pathways in the third quarter valued at $371,000. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways Price Performance

Shares of CMPS stock traded down $0.01 on Tuesday, hitting $3.36. 1,205,630 shares of the company's stock were exchanged, compared to its average volume of 1,637,319. The company has a 50 day moving average of $4.38 and a 200 day moving average of $5.91. The stock has a market cap of $229.89 million, a P/E ratio of -1.53 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.04. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. On average, equities research analysts predict that COMPASS Pathways will post -2.33 EPS for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.